The standard 0.5 to 1.0 mg dose of adrenaline used in cardiac resuscitation may be inadequate on the basis of theoretical and experimental evidence. Well designed clinical trials are indicated to test the hypothesis that higher doses of adrenaline could be more effective in specific subgroups of people experiencing cardiac arrest. The success in resuscitation is related to the aortic diastolic pressure and the effectiveness of adrenaline relates to its peripheral vasopressor effect. Other catecholamines such as noradrenaline may be more efficacious, as could be non-adrenergic vasopressors. Clinical studies are required, however, to evaluate these potential alternatives.
There has been considerable investigation into the use of exogenous adrenaline in cardiac arrest, and to a lesser extent, other vasopressors. The dose of adrenaline has been debated for many years and many practitioners admit to using doses much higher than those recommended by the standard guidelines on the subject.
The current recommendation is 0.5 to 1.0 mg adrenaline intravenously every five minutes, giving a dose of 0.007 to 0.014 mglkg body weight in a 70 kg person, 0.005 to 0.0 I mglkg in a 90 kg person. 1 This review concentrates on type and dosage of vasopressor used in cardiopulmonary resuscitation (CPR).
Theoretical considerations of myocardial requirements during CPR
The level of myocardial blood flow required to meet the metabolic demands of the heart and to maintain tissue viability ranges from approximately 75 mlIminllOO g during normal sinus rhythm down to 10 mlIminllOO g during asystole. 2 Ralston and co-workers showed that after a twenty-minute period of CPR, none of those animals in which the myocardial perfusion was less than 13 mlIminllOO g survived. 3 Blood flow to the myocardium is determined by the pressure differential across the vascular bed. Coronary blood flow during closed chest CPR occurs mainly during the relaxation period and it is determined by the pressure gradient across the myocardium, i.e. the difference between aortic diastolic and right atrial diastolic pressure. 4 A number of factors influence the coronary vascular resistance during CPR, in particular vasodilating effects of metabolic changes and probable sympathetic nervous activation. Opposing this effect is the muscle tone and the defibrillating myocardium, probably coronary artery stenosis and adrenergic stimulation. 5 An aortic diastolic pressure of at least 30 mmHg and a coronary perfusion pressure of at least 20 mmHg is required to achieve a myocardial blood flow high enough to permit restoration of spontaneous circulation in animals during CPR. [6] [7] [8] Even after giving adrenaline, aortic diastolic pressure is the major determinant in coronary perfusion pressure because there is no significant change in right atrial pressure following adrenaline administration. 9 Adrenergic stimulation during CPR (i) Sympathetic nervous system effect on the coronary arteries Local mechanisms are the prime regulators of coronary blood flow, but the autonomic nervous system does play a role. 10 In a review on adrenergic control of coronary arteries, Morland and Bohr conclude the autonomic nervous system has the potential for either vasoconstriction or vasodilation. 11 The ab a2, Pb P2 receptors have a different distribution within the coronary vasculature, with the large coronary arteries having a larger proportion of receptors a1 and a2 and minimal Padrenergic activity. In contrast the small coronary arteries exhibit negligible a-adrenergic activity and demonstrate predominantly It-adrenergic activity. These variations of distribution are confirmed in dogs, pigs, rabbits, monkeys and humans. It appears that the post-junctional a2 receptors play a larger role in adrenergic vasoconstriction than do the a I receptors. II Heusch and Deussen found that myocardial ischaemia distal to a severe coronary artery stenosis is secondary to vasoconstriction mediated by postjunctional a2 receptors, without al influence. 12 However, a2 agonists decrease coronary blood flow even in underperfused vessels.
Interestingly, myocardial blood flow is not impaired with noradrenaline-induced ayreceptor stimulation of the coronary arteries. 5 This may be partially explained by l3-receptor stimulation by noradrenaline. Classically 13 receptors are classified as 131 on the myocardium and 132 in the vasculature. However, studies in dogs indicate that the coronary artery receptors are of the 131 subclass. II Although some studies I 1,13 indicate that 132 receptors mediate coronary vasodilatation, the overall data supports I3I-vasodilatation in the coronary arteries. Cohen and co-workers provide experimental evidence in the canine model that the predominant effect of adrenergic activation is relaxation of the coronary arteries by activation of the 131 receptor. 14 Post-junctional al receptors that oppose the 13adrenergic effect of noradrenaline are located only in the proximal vessels. 15 Prejunctional a2 receptors limit the dilator action on the nerves by inhibiting noradrenaline release and are present in both proximal and distal vessels. Human coronary vascular smooth muscle may also have a predominantly l3-adrenergic response to sympathetic nerve stimulation. 15 The confusion as to the exact effects of different receptor stimulation in the coronary circulation may be because a and 13 receptors are different allosteric figurations of the same macromolecule and can be transformed between states by local factors such as temperature. 16 ,17 Furthermore, in the failing heart there is a recognised 'down regulation' of the 131adrenergic receptors, along with the uncoupling of the 132-adrenergic receptors in the myocardium. 18 This 'down regulation' relates to an actual decrease in the density of /3 receptors which is present in mild heart failure and becomes progressively reduced as the heart failure progresses. It may be that there is an associated 'down regulation' of /3 receptors in the coronary vasculature, although this has not been demonstrated to date.
(ii) a-adrenergic stimulation of the peripheral vasculature As the emphasis is on maintaining aortic diastolic pressure in ePR, the use of vasopressors to cause vasoconstriction in the peripheral circulation (especially skin and skeletal muscle) is justified. [19] [20] [21] [22] [23] The collapse of the carotid artery during ePR and the fact that this is reversed by peripheral vasoconstriction may also be an important factor in obtaining a successful outcome. 21 ,24,25 The supposition that a-adrenergic stimulation causing peripheral vasoconstriction is the only effect of adrenaline is a simplified one. 26 As the effects of at and a2 receptor activators are generally being evaluated, a complex series of interactions is becoming evident (Table 1) . The effects of a number of adrenergic agonists during ePR have been analysed. These agents include adrenaline, noradrenaline, methoxamine, phenylephrine, dopamine, clonidine, isoprenaline and several experimental agonists and antagonists ( Table 2 ). An overall picture is slowly emerging. Those agents with strong a-agonist properties are generally more effective than those with pure j3-agonist activities, but even within the a-agonist group there are interesting differences.
For example, adrenaline and noradrenaline both raise the aortic diastolic pressure by approximately 40 mmHg, whereas other a agonists will not. [28] [29] [30] The pure at agonists methoxamine and phenylephrine do not result in a consistent significant improvement in aortic diastolic pressure. 29 ,3O There are some differences in rapidity of response in ePR between adrenaline and noradrenaline, which are both at and a2 agonists, and the pure at agonists, which may result from the a2 difference. In vascular smooth muscle both the at and a2 receptors are responsible for altering the peripheral vascular resistance, with both a\ and a2 receptors present.
Response to both of these receptors situated post-junctionally is vasoconstriction. Brown and Weiman in an extensive review conclude that in hypoxic states there is a selected decrease in the number of a\ binding sites. 2 ,31 This results in a more significant contribution to vasomotor tone in an hypoxic state by the a2 receptor -hence the relative lack of effect by methoxamine and phenylephrine. 5
Animal resuscitation studies
Over 80 years ago, Crile and Dolley demonstrated with dogs, that 'inauguration' of heart beat in the cardiac arrest situation was dependent upon increased pressure in the coronary arteries. Adrenaline was a very useful agent in this situation. 32 They used doses of 0.06-1.25 mg/kg body weight in successful resuscitation and used intra-arterial administration. In 1962, Redding and Pearson demonstrated that during circulatory arrest due to asphyxia persisting for one minute, only two out of ten dogs could be resuscitated by artificial ventilation and closed chest massage. 33 However, when the duration of arrest was increased to five minutes and intra-cardiac adrenaline used, all ten dogs were resuscitated. Three years later in experiments on a large number of dogs, these same researchers recognised a relationship between survival from cardiac arrest and aortic diastolic pressure. 26 Less than 30% were resuscitated without the use of adrenaline, and in these dogs, the aortic diastolic pressure was < 20 mmHg.
After adrenaline, the diastolic pressure rose to over 30 mmHg and 100% of the animals were resuscitated. In all of these experiments, the authors stated that a dose of 0.2 mg was suboptimal and 1.0 mg was required. 34 ,35 The effective dose range was from 0.07 to 0.15 mg adrenaline per kilogram body weight.
Although high levels of endogenously released catecholamines occur during cardiac arrests,36,37 they are not sufficient to maintain blood pressure in pigs. 38 Using dogs, Kern and co-workers demonstrated that successful resuscitation occurred in those with the greater increase in plasma adrenaline levels following exogenous adrenaline administration. 39 Lindner and co-workers demonstrated that after a four-minute period of cardiopulmonary arrest in pigs, coronary perfusion pressure, myocardial blood flow, and resuscitation successes were increased when adrenaline was given at a dose of 0.045 mg/kg in comparison to 0.015 mglkg, but that a further increase to 0.09 mg/kg did not lead to any greater improvement. 7 Although ~ agonists vasodilate the coronary arteries, the role in the cardiac arrest situation is uncertain. Studies in dogs have demonstrated that isoprenaline, a pure ~ agonist, resulted in lower rates of resuscitation than when no drugs at all were given.
In a study on 110 mongrel dogs, the relative efficacies of adrenaline, isoprenaline and other agents in resuscitating the dogs from asphyxial arrest were compared. With isoprenaline, a pure ~ agonist, no dogs were resuscitated, whereas with adrenaline the success rate was 100%. In summary the large number of animal studies indicate that: • adrenaline is effective in improving resuscitation rates;
• doses of < 0.02 mg/kg body weight of adrenaline are relatively ineffective; • adrenaline works by increasing aortic diastolic pressure; • other a-adrenergic agents can be beneficial, and • pure ~-adrenergic agents are less effective than no treatment.
Human resuscitation studies
The most commonly used vasopressor in CPR is adrenaline. The American Heart Association recommend a dose of 0.5 to 1.0 mg (0.007-0.014 mglkg in a 70 kg adult), intravenousiy every five minutes in their Advanced Life Support Protocol. 1
The basis for this recommended dose is not clear. 21 ,35,40,41 Although this recommendation has become the gold standard in the world, many investigators and clinicians consider it inadequate. Numerous anecdotal reports have suggested that high-dose adrenaline be used in human CPR.42. 45 Gonzales 46 studied ten prehospital cardiac arrest patients, determining vasopressor response and change in end-tidal C02 concentration after incremental (I, 3, 5 mg) doses of intravenous adrenaline given five minutes apart during closed chest CPR. All patients were in ventricular fibrillation when the paramedic arrived and did not respond to standard Advanced Cardiac Life Support (ACLS). Diastolic BP and systolic BP were directly related to the dose of adrenaline, and endtidal C02 decreased progressively with each dose of adrenaline. The doses were higher than those currently recommended.
Barton and Callaham reviewed 49 patients with cardiac arrest and found that 29 (59%) of those given high-dose adrenaline regained circulation compared with 7 (14%) of those given standard dose. 47 In this study the high-dose of adrenaline was given late in the arrest in a non-randomised fashion, and ultimately did not enhance survival.
In a further study the same investigators reviewed 63 of their patients who survived longer than six hours after resuscitation from cardiac arrest.48 Half received standard doses and half higher doses; the largest dose (in a neurological intact survivor) was 105 mg. They did not identify adverse effects of high dose adrenaline. Their current management is to give 200 ~g/kg (15 mg for a 70 kg person) by intravenous push every five minutes.
In a recent study, Lindner and co-workers reviewed 68 adults with cardiac arrest (asystole and electro-mechanical dissociation) who were treated with either the standard (1.0 mg) or high-dose (5 mg) adrenaline. 49 If the first dose of adrenaline failed (1.0 or 5 mg), standard Advanced Cardiac Life Support (ACLS) guidelines were applied in all cases, i.e. administration of adrenaline (1.0 mg). An initial high-dose adrenaline administration was associated with higher resuscitation success (16 of 28) than initial standard dose (6 of 40). However, hospital discharge rates were not significantly different between the groups despite the initial higher resuscitation rates.
Disadvantages of high-dose adrenaline in CPR
Although high-dose adrenaline is advocated by some, there may be problems associated with its use.
(A) Vasopressors and oxygen consumption
Lindner found that adrenaline administration in pigs with ventricular fibrillation undergoing openchest CPR resulted in increased myocardial oxygen delivery, but also in a simultaneous increase in consumption. 50 In contrast, noradrenaline led to an improvement in the ratio of myocardial oxygen delivery and consumption. Livesay found in dogs that adrenaline may hinder subendocardial blood flow in the defibrillating myocardium, and that its inotropic properties may even worsen myocardial ischaemia by increasing myocardial oxygen consumption at a time when supply is limited. 4o (B) Myocardial tissue damage secondary to highdose adrenaline
Post mortem studies on the hearts of animals and people dying after prolonged resuscitation demonstrate a recognisable pattern of myocardial injury characterised by contraction band necrosis, focal haemorrhage, and coagulation necrosis. 51 -53 In a study on the autopsies of 26 children, the hearts of 17 in whom attempted resuscitation with adrenaline and/or defibrillation was performed were compared with the remainder who did not. The conclusion was that myocardial injury occurred with defibrillation alone, and catecholamines alone, and when used together there was a statistically significant increase in tissue destruction. 53 (C) Adverse effects of high-dose adrenaline in outcome of ventricular fibrillation A study by Marwick and others in 1988 questions the use of high-dose adrenaline in ventricular Anaesthesia and Intensive Care. Vol. 20. No. 4. November. 1992 fibrillation. 54 In this study they compared the outcome of early high-dose adrenaline in 77 patients with the outcome of standard-dose adrenaline or no adrenaline in 133 patients. A reduction in the immediate survival of patients in the high-dose adrenaline group was observed, 22% compared to 43% in the standard dose or no-adrenaline group. They concluded that the use of early high-dose adrenaline in ventricular fibrillation cardiac arrest was associated with a reduction in immediate survival. They argue that the basis for this result could be the known sympathethic nervous system role in the genesis of ventricular fibrillation. 55 
Alternative agents to adrenaline in CPR
The studies above indicate that a-agonist properties are necessary to achieve a significantly improved outcome from CPR although methoxamine and phenylephrine, pure a1 agonists, are not as effective as adrenaline. 2 ,56,57 Another adrenergic agonist which was evaluated in CPR is dopamine. [58] [59] [60] Using the dog model, both adrenaline and dopamine restored the circulation in 95% of subjects, but massive doses of dopamine at 200 ~g/kg were used. 58 Lindner using pigs compared 45 ~g/kg of dopamine with 45 ~g/kg of adrenaline, dopamine producing faster effects (174 seconds compared with 667 seconds) with less hypertension and tachycardia. 61 As noradrenaline has similar agonist activity to adrenaline it should be a reasonable alternative in resuscitation. In the pig, noradrenaline is as effective as adrenaline and appears to act more rapidly in ventricular fibrillation. 62 In comparing the relative effects on myocardial oxygen delivery and consumption in the pig model, Lindner demonstrated a relative benefit from noradrenaline. At doses of 45 ~g/kg both agonists augmented myocardial blood flow during open chest cardiac massage. However, the myocardial oxygen consumption increased significantly more after the use of adrenaline compared with noradrenaline, with the extraction ratio remaining the same with adrenaline. Noradrenaline leads to an improvement in the ratio of myocardial oxygen demands and myocardial oxygen delivery. These findings suggest that noradrenaline is preferable to adrenaline and this may be due to the marked selectivity for /31 receptors by noradrenaline, resulting in more coronary artery dilatation. 50 Although this is a promising lead, there is insufficient evidence to warrant the use of noradrenaline in place of adrenaline in humans at this stage.
The emphasis on adrenergic agents in CPR may be a narrow perspective, since nonadrenergic vasopressors are not yet available. Araujo and co-workers recently suggested a role for angiotensin 11. In dogs with fibrillatory arrest, angiotensin 11 was very effective in restoring spontaneous circulation during CPR. They report similar effects in dogs with asphyxial arrest. 63 There is a recognised interaction between adrenaline and angiotensin 11 with adrenaline stimulating the renin-angiotensin system (u-and l3-mediated effect) and angiotensin 11 facilitating the release of catecholamines from the adrenal medulla and sympathetic nerves. 27 ,64 There are no reports of antiogensin 11 being used in CPR in human subjects.
In conclusion, the currently recommended doses of 0.5 to 1.0 mg adrenaline every five minutes may be inadequate for vasopressor therapy in cardiac resuscitation. Animal studies and small series in humans suggest that intravenous boluses of 3 to 15 mg are more effective; however, no large clinical trials have yet been carried out.
As to whether alternative vasopressors should be used in preference to adrenaline the answer is clearer -it is reasonable to continue using adrenaline at this time.
With respect to alternative vasopressors it would seem that the pure u, agonists, methoxamine and phenylephrine and the pure 13, agonist isoprenaline should not be used. Noradrenaline and dopamine may prove to be more advantageous than adrenaline (particularly noradrenaline), although future human studies are awaited. The nonadrenergic vasopressor angiotensin 11 may also prove to be more efficacious than adrenaline.
